Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mimedx (MDXG) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Mimedx (MDXG) over the last 16 years, with Q3 2025 value amounting to $148.0 million.

  • Mimedx's Shares Outstanding (Weighted Average) rose 69.83% to $148.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $148.0 million, marking a year-over-year increase of 69.83%. This contributed to the annual value of $147.0 million for FY2024, which is 2616.71% up from last year.
  • As of Q3 2025, Mimedx's Shares Outstanding (Weighted Average) stood at $148.0 million, which was up 69.83% from $147.8 million recorded in Q2 2025.
  • In the past 5 years, Mimedx's Shares Outstanding (Weighted Average) ranged from a high of $148.0 million in Q3 2025 and a low of $109.4 million during Q1 2021
  • Its 5-year average for Shares Outstanding (Weighted Average) is $125.5 million, with a median of $115.9 million in 2023.
  • Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first soared by 2797.74% in 2024, then rose by 29.53% in 2025.
  • Mimedx's Shares Outstanding (Weighted Average) (Quarter) stood at $110.4 million in 2021, then rose by 2.32% to $112.9 million in 2022, then increased by 3.18% to $116.5 million in 2023, then grew by 26.17% to $147.0 million in 2024, then increased by 0.72% to $148.0 million in 2025.
  • Its last three reported values are $148.0 million in Q3 2025, $147.8 million for Q2 2025, and $147.3 million during Q1 2025.